睾酮替代療法市場機會、成長動力、行業趨勢分析和 2025 - 2034 年預測

2024 年全球睪固酮替代療法市場規模達到 19 億美元，預計 2025 年至 2034 年期間的複合年成長率為 4.2%。隨著越來越多的男性尋求解決睪固酮缺乏症的方法，治療方法的進步和荷爾蒙替代療法的日益接受正在推動需求。

宣傳活動的增加、醫療保健基礎設施的改善以及以患者為中心的藥物輸送系統使得睾酮替代療法更加容易獲得。個人化醫療的轉變和治療配方的創新進一步加速了市場發展勢頭。這些發展確保了睪固酮替代療法市場仍是滿足荷爾蒙缺乏症患者需求的重點。

2024 年，注射劑佔據市場主導地位，創造 11 億美元的收入。這些產品由於能夠提供穩定且可預測的睪固酮水平而優於凝膠和貼片。由於注射劑具有可靠的生物利用度、易於調整劑量以及客製化治療計劃的能力，已成為患者和醫療保健提供者的首選。這些好處有助於改善患者的治療效果，確保注射劑在睪固酮替代療法市場的領導地位。

在活性成分中，環戊丙酸睪酮佔據領先地位，2024 年的收入為 6.361 億美元，預計到 2034 年的複合年成長率為 4.5%。這種便利性提高了患者的依從性，並使該化合物成為尋求有效且易於管理的治療方案的醫療保健提供者的首選。

2024 年美國睪固酮替代療法市場收入將達到 7.361 億美元，預測期內預計複合年成長率為 3.5%。完善的醫療保健基礎設施、領先製藥商的存在以及優惠的報銷政策支持了市場的成長。凝膠、貼片和注射等給藥方式的創新提高了藥物的可及性和患者的接受度。對這些先進療法的需求不斷成長，凸顯了該國在全球睾酮替代療法市場的主導地位。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 性腺功能低下盛行率不斷上升
    • 藥物傳輸的進展
    • 對性腺功能低下的認知不斷提高
    • 老齡人口不斷擴大
  • 產業陷阱與挑戰
    • 副作用和風險
• 成長潛力分析
• 2024 年定價分析
• 監管格局
• 報銷場景
• 技術格局
• 管道分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按產品類型，2021 年至 2034 年

• 主要趨勢
• 注射劑
• 專題
• 其他產品類型

第 6 章：市場估計與預測：按活性成分，2021 年至 2034 年

• 主要趨勢
• 環戊丙酸睪酮
• 睪固酮
• 庚酸睪酮
• 十一酸睪酮
• 其他活性成分

第 7 章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 傳統實體店
• 電子商務

第 8 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• Antares Pharma
• Cipla
• Eli Lilly & Co.
• Endo International
• Ferring Pharmaceuticals
• Halozyme
• Lupin
• Marius Pharmaceuticals
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals
• Tolmar

The Global Testosterone Replacement Therapy Market reached USD 1.9 billion in 2024 and is set to expand at a CAGR of 4.2% between 2025 and 2034. This growth is fueled by the rising incidences of hypogonadism and increased awareness about its diagnosis and treatment options. As more men seek solutions for testosterone deficiency, advancements in therapeutic approaches and growing acceptance of hormone replacement therapies are driving demand.

A surge in awareness campaigns, improved healthcare infrastructure, and patient-focused drug delivery systems have made testosterone replacement therapy more accessible. The shift toward personalized medicine and innovations in treatment formulations are further accelerating market momentum. These developments ensure that the testosterone replacement therapy market remains a key focus in addressing the needs of patients suffering from hormonal deficiencies.

In 2024, injectables dominated the market, generating USD 1.1 billion in revenue. These products outperform gels and patches due to their ability to provide stable and predictable testosterone levels. With reliable bioavailability, ease of dosage adjustment, and the capability to tailor treatment plans, injectables have become the preferred choice for both patients and healthcare providers. These benefits contribute to better patient outcomes, securing injectables' leadership position in the testosterone replacement therapy market.

Among active ingredients, testosterone cypionate led the segment, accounting for USD 636.1 million in revenue in 2024, and anticipated to grow at a CAGR of 4.5% through 2034. Known for its extended duration of action, testosterone cypionate typically requires injections only once every one to two weeks, significantly reducing the frequency of administration. This convenience improves patient adherence and has established the compound as a go-to option for healthcare providers seeking effective and manageable treatment solutions.

The U.S. testosterone replacement therapy market reached USD 736.1 million in revenue in 2024, with a projected CAGR of 3.5% over the forecast period. The market's growth is supported by a well-established healthcare infrastructure, the presence of leading pharmaceutical manufacturers, and favorable reimbursement policies. Innovations in delivery methods, such as gels, patches, and injections, have increased accessibility and patient acceptance. Rising demand for these advanced therapies underscores the country's dominant position in the global testosterone replacement therapy market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hypogonadism
    • 3.2.1.2 Advancements in drug delivery
    • 3.2.1.3 Growing awareness about hypogonadism
    • 3.2.1.4 Expanding aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and risks
• 3.3 Growth potential analysis
• 3.4 Pricing analysis, 2024
• 3.5 Regulatory landscape
• 3.6 Reimbursement scenario
• 3.7 Technology landscape
• 3.8 Pipeline analysis
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Injectables
• 5.3 Topicals
• 5.4 Other product types

Chapter 6 Market Estimates and Forecast, By Active Ingredients, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Testosterone cypionate
• 6.3 Testosterone
• 6.4 Testosterone enanthate
• 6.5 Testosterone undecanoate
• 6.6 Other active ingredients

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Brick & mortar
• 7.3 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Antares Pharma
• 9.3 Cipla
• 9.4 Eli Lilly & Co.
• 9.5 Endo International
• 9.6 Ferring Pharmaceuticals
• 9.7 Halozyme
• 9.8 Lupin
• 9.9 Marius Pharmaceuticals
• 9.10 Pfizer
• 9.11 Sun Pharmaceutical Industries
• 9.12 Teva Pharmaceuticals
• 9.13 Tolmar